Update: Small Cap Biotech Important FDA Action Dates for September

Here are the FDA action dates for September, enjoy and now go play!
Sept. 1
-FDA advisory Committee meets to review Vion Pharmaceuticals' (biotech ticker: VION) Onrigin, drug for treatment of acute myeloid leukemia.

Sept. 2
-FDA advisory Committee meets to review Allos Therapeutics' (biotech ticker: ALTH) pralatrexate, drug for treatment of lymphoma.

-FDA approval action date for Endo Pharmaceuticals' (biotech ticker: ENDP) Nebido, a long-acting testosterone replacement therapy.

Sept. 7
-FDA approval action date for Spectrum Pharmaceuticals' (biotech ticker: SPPI) Zevalin, a drug for non-Hodgkin's lymphoma.

Sept. 11
-FDA approval action date for Salix Pharmaceuticals’ (biotech ticker: SLXP) Metozolv (Metoclopramide), a drug for treatment of gastroesophageal reflux who fail to respond to conventional therapy

Sept. 12
-FDA approval action date for ISTA Pharmaceuticals’ (biotech ticker: ISTA) Bepreve, a drug for ocular itching associated with allergic conjunctivitis.

Sept. 16
-FDA Advisory Committee meets to review Auxilium Pharmaceutical's (biotech ticker:AUXL) Xiaflex for advanced Dupuytren's disease.

-FDA approval action date for Theravance's (biotech ticker: THRX) antibiotic Telavancin.

Sept. 24
-FDA approval action date for Eurand Pharmaceuticals' (biotech ticker: EURX) Zenpep, a drug for pancreatic insufficiency.

-FDA approval action date for Allos Therapeutics' (biotech ticker: ALTH) Pralatrexate, a drug for peripheral T-cell lymphoma.